Alkermes reviewing options after Lundbeck makes unsolicited bid for Avadel
Nov 14 (Reuters) - Alkermes ALKS.O said on Friday it is reviewing its options with advisers after Avadel Pharmaceuticals AVDL.O disclosed it had received an unsolicited takeover proposal from Danish pharmaceutical company Lundbeck. In October, Alkermes had said it will buy Avadel in a deal worth up to $2.1 billion, aiming to enter the sleep medicine market (Reporting by Kamal Choudhury in Bengaluru; Editing by Krishna Chandra Eluri) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Avadel Pharmaceuticals
See all newsBrief: Alkermes PLC Completes Acquisition Of Avadel Pharmaceuticals PLC, Accelerating Entry Into Sleep Medicine Market
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 08:10 AM
H Lundbeck steps down from takeover for Avadel, shares rise 3%
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet